Overview

* Eton Q3 2025 product sales rise 129% yr/yr to $22.5 mln

* Company reports Q3 non-GAAP EPS of $0.04, despite GAAP EPS loss of $0.07

* ET-600 NDA accepted by FDA, PDUFA date set for Feb 25, 2026

Outlook

* Company expects to launch ET-600 in Q1 2026

Result Drivers

* PRODUCT SALES GROWTH - Eton's Q3 2025 product sales increased by 129% yr/yr, driven by ALKINDI SPRINKLE, Carglumic Acid, INCRELEX, and GALZIN

* INCRELEX RELAUNCH - INCRELEX relaunch exceeded expectations, becoming the largest revenue contributor in Q3 2025

* GALZIN ADOPTION - GALZIN relaunch saw strong adoption, with accelerated uptake in Q3 2025

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.07

Q3 Net -$1.93

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for Eton Pharmaceuticals Inc ( ETON ) is $29.00, about 33.6% above its November 5 closing price of $19.25

* The stock recently traded at 25 times the next 12-month earnings vs. a P/E of 18 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)